Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.58 |
| ▸ | CA2 | P00918 | 9/20 | 0.58 |
| ▸ | CA9 | Q16790 | 7/20 | 0.58 |
| ▸ | CA12 | O43570 | 6/20 | 0.58 |
| ▸ | PDE4A | P27815 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 3/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20936503 | 0.90 | CA1 (0.46) | CA1CA2CA9CA12PDE4A | |
| SCHEMBL8076402 | 0.81 | CA1 (0.62) | CA1CA2CA9CA12PDE4A | |
| SCHEMBL20788610 | 0.80 | CA1 (0.59) | CA1CA2CA9CA12CA4 | |
| SCHEMBL23219874 | 0.79 | CA1 (0.58) | CA1CA2CA9CA12PDE4A | |
| SCHEMBL12317636 | 0.79 | CA1 (0.69) | CA1CA2CA9CA12CA4 | |
| SCHEMBL20936552 | 0.78 | CA1 (0.53) | CA1CA2CA9CA12PDE4A | |
| SCHEMBL24526218 | 0.78 | CA1 (0.53) | CA1CA2CA9CA12CA4 | |
| Hydrochloric Acid SCHEMBL19838208 | 0.77 | CA1 (0.67) | CA1CA2CA9CA12CA4 | |
| SCHEMBL18362459 | 0.77 | CA1 (0.54) | CA1CA2CA9CA12PDE4B | |
| SCHEMBL12317682 | 0.77 | CA1 (0.60) | CA1CA2CA9CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827657-B2 | Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof | Boehringer Ingelheim Animal Health USA Inc. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20220194965-A1 | BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | BORAH, INC. | 2022-06-23 | — | — | US | disclosed |
| WO-2018024793-A1 | METHOD OF CROSSLINKING GLYCOSAMINOGLYCANS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827657-B2 | Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof | JAK3, JAK1, JAK2 | CA1 2675/4885CA2 1365/4885CA9 897/4885 |
| US-20220194965-A1 | BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | JAK3, JAK1, JAK2 | CA1 2675/4885CA2 1365/4885CA9 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.